Steven Jay Isakoff MD PhD

Oncology•Boston, MA

Breast Cancer

Assistant Professor in Medicine, Massachusetts General Hospital

Join to View Full Profile

55 Fruit StYawkey 9ABoston, MA 02114
Phone+1 617-726-6500
Fax+1 617-643-0589

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2006
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2000 - 2002
New York University School of MedicineClass of 2000, MD, PhD
Princeton UniversityAB, Molecular Biology, Cum Laude, 1987 - 1991

Certifications & Licensure

MA State Medical License 2003 - 2026
American Board of Internal Medicine Medical Oncology

Clinical Trials

Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response Start of enrollment: 2007 Jun 01
Completed
Phase 2
TOBI to Monitor Response to Neoadjuvant Therapy in Breast Cancer Start of enrollment: 2008 Aug 01
Completed
Not Applicable
ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
COMPLETED
PHASE2
Trastuzumab and Vinorelbine in Advanced Breast Cancer Start of enrollment: 2010 Nov 01
Terminated
Phase 2
PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer Start of enrollment: 2010 Nov 01
Completed
Phase 1
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer Start of enrollment: 2012 Jun 13
Completed
Phase 2
Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
COMPLETED
PHASE2
A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors Start of enrollment: 2012 Nov 01
Completed
Phase 1
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
ACTIVE_NOT_RECRUITING
PHASE2
Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer Start of enrollment: 2013 Sep 01
Terminated
Phase 2
Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases Start of enrollment: 2014 Nov 01
Completed
Phase 2
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
ACTIVE_NOT_RECRUITING
PHASE1
An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer Start of enrollment: 2016 Oct 01
Unknown status
Phase 2
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer Start of enrollment: 2017 Mar 31
Active, not recruiting
Phase 2
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer Start of enrollment: 2017 Dec 12
ACTIVE_NOT_RECRUITING
PHASE1
A Pilot Study of Tomographic Optical Breast Imaging (DBT-TOBI) to Monitor Response to Neoadjuvant Therapy Start of enrollment: 2019 Feb 01
ACTIVE_NOT_RECRUITING
NA
Onvansertib + Paclitaxel in TNBC Start of enrollment: 2022 Sep 30
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Roles: Contact, Principal Investigator
Niraparib + Dostarlimab in BRCA Mutated Breast Cancer Start of enrollment: 2020 Dec 18
RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer Start of enrollment: 2021 Jul 21
RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies.
Yael Bar, Geoffrey Fell, Aylin Dedeoglu, Natalie Moffett, Neelima Vidula
NPJ Breast Cancer. 2025-03-11
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER).
Laura M Spring, Lauren Scarpetti, Arielle J Medford, Andrzej Niemierko, Amy Comander
NPJ Breast Cancer. 2025-01-07
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.
Rachel O Abelman, Bogang Wu, Haley Barnes, Arielle Medford, Bryanna Norden
Clinical Cancer Research. 2025-01-02

Press Mentions

When to Get First Mammogram? Doctor Explains Latest AdviceMay 12th, 2023
Neoadjuvant Niraparib Demonstrates Promising Antitumour Activity and Safety in Patients with Localised HER2-Negative, BRCA-Mutated Breast CancerAugust 10th, 2022
Ribociclib Dose Modifications Do Not Affect OS in Patients with Hr+/her2 Advanced Breast CancerJune 21st, 2022
Join now to see all